From Patterson's 19 June 09 Research Note (page 10):
A study by Czerepak et Ryser established a biotech failure rate of 74% (although we would make the
observation that aspects of the treatment have been significantly de-risked, as a result of the current
widespread use of Artmether in tablet form). This implies a risk adjusted value for Eastland® of $0.26.
If phase III trials are successful and after other appropriate submissions (below uses FDA approvals
as a proxy albeit not relevant for ArtiMistTM), then Eastland® valuation would rise to ~$1.50 on a derisked
commercialised basis.
From Patterson's 19 June 09 Research Note (page 10):A study by...
-
- There are more pages in this discussion • 23 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add EMS (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
2.5¢ |
Change
-0.002(7.41%) |
Mkt cap ! $2.841M | |||
| Open | High | Low | Value | Volume |
| 2.6¢ | 2.6¢ | 2.4¢ | $18.33K | 746.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 150000 | 2.1¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.5¢ | 315040 | 2 |
View Market Depth
| Last trade - 16.10pm 02/08/2024 (20 minute delay) ? |
| EMS (ASX) Chart |